1.80
+0.02(+1.12%)
Currency In USD
| Previous Close | 1.78 |
| Open | 1.77 |
| Day High | 1.82 |
| Day Low | 1.73 |
| 52-Week High | 4.44 |
| 52-Week Low | 1.18 |
| Volume | 245,895 |
| Average Volume | 476,483 |
| Market Cap | 525.08M |
| PE | -3.33 |
| EPS | -0.54 |
| Moving Average 50 Days | 1.83 |
| Moving Average 200 Days | 2.21 |
| Change | 0.02 |
If you invested $1000 in ProKidney Corp. (PROK) since IPO date, it would be worth $178.04 as of December 26, 2024 at a share price of $1.8. Whereas If you bought $1000 worth of ProKidney Corp. (PROK) shares 2 years ago, it would be worth $292.68 as of December 26, 2024 at a share price of $1.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2024 12:30 PM GMT
WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
GlobeNewswire Inc.
Nov 05, 2024 12:30 PM GMT
WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
GlobeNewswire Inc.
Oct 14, 2024 11:30 AM GMT
WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Comp